Trials / Withdrawn
WithdrawnNCT03771885
BI 705564 in Patients With Systemic Lupus Erythematosus (SLE)
A Phase Ib, Multicentre, Randomised, Double-blind, Placebo Controlled, 8 Week Crossover Study to Assess the Safety, Tolerability and Pharmacokinetics of Orally Administered BI 705564 in Patients With Systemic Lupus Erythematosus.
- Status
- Withdrawn
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Boehringer Ingelheim · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The main objective of this study is to assess the safety, tolerability and pharmacokinetics of orally administered BI 705564 in patients with systemic lupus erythematosus
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BI 705564 | Film-coated Tablet |
| DRUG | Placebo | Film-coated Tablet |
Timeline
- Start date
- 2019-03-16
- Primary completion
- 2019-12-21
- Completion
- 2020-01-07
- First posted
- 2018-12-11
- Last updated
- 2021-11-15
Source: ClinicalTrials.gov record NCT03771885. Inclusion in this directory is not an endorsement.